Global Budesonide Inhaler Market Insights Forecasts to 2033

• The Global Budesonide Inhaler Market Size was Estimated at USD 6.67 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 6.51% from 2023 to 2033
• The Worldwide Budesonide Inhaler Market Size is Expected to Reach USD 12.53 Billion by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

Get more details on this report -

Request Free Sample PDF

The Global Budesonide Inhaler Market Size is predicted to exceed USD 12.53 Billion by 2033, growing at a CAGR of 6.51% from 2023 to 2033. The market growth is owing to rising awareness of respiratory diseases through government and private programs, innovations in drug delivery technology, and rising cases of asthma in the pediatric population.  

 

Market Overview

The budesonide inhaler market involves the production and commercialization of inhalers containing budesonide, a corticosteroid medication used to treat respiratory diseases such as asthma and COPD. Budesonide treats asthma over time and prevents the disease from progressing worsened by reducing lung inflammation. Frequent inhalation of budesonide minimizes the frequency and intensity of asthma episodes. Nevertheless, it continues to trigger an asthma attack that began earlier. Budesonide is marketed as a suspension that is administered with a special jet nebulizer. It has been reported that budesonide inhalers are safe to use while pregnant. Budesonide and other corticosteroids aid in enhancing lung airflow and lowering airway inflammation. Along with other asthma drugs, inhaled budesonide can help widen constricted airways. Owing to the rise in respiratory illnesses, improved product quality, and increasing initiatives to conduct research and development, the market for budesonide inhalers is anticipated to expand. Various distribution channels, regulatory approvals, and the possibility of future improvements in inhalers are all factors contributing to the market's future expansion. Seasonal asthma is another effect of climate change and can be a major source of respiratory ailments. Since the elderly and children are more susceptible to the effects of climate change, inhalers are good for their health and promote market expansion.

 

The rising occurrence of asthma leads to an increase in demand for medications for the management of asthma, resulting in the budesonide inhaler market growth. For instance, the data provided by the National Library of Medicine states that asthma is a prevalent non-communicable disease affecting around 300 million people globally, ranking 16th among leading causes of disability and 28th among burden of disease. Therefore, all the above-mentioned features of budesonide inhaler accelerate the budesonide inhaler market growth.

 

Report Coverage

This research report categorizes the global budesonide inhaler market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global budesonide inhaler market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global budesonide inhaler market.

 

Driving Factors:

Rising incidence of airway diseases (respiratory diseases):

The need for efficient treatments is being driven by the global increase in respiratory conditions, including asthma and COPD, which renders the budesonide inhaler market industry essential. The need for medication to reduce inflammation and symptoms grows increasingly critical as environmental causes, urbanization, and lifestyle changes all contribute to respiratory problems. A common corticosteroid choice, budesonide inhalers assist lower airway inflammation, which enhances patients' quality of life and reduces symptoms. Technological developments in inhalers are improving their usability and increasing adherence to recommended treatments.

 

Innovations in inhaler devices and raising awareness about the management of asthma:

The market for budesonide inhalers is growing as a result of technical developments that improve effectiveness and user-friendliness. In addition to improving patient management and medication compliance, smart inhalers with tracking systems provide real-time health data for preventative care. The demand for budesonide inhalers is experiencing growth as a result of enhanced knowledge and instruction regarding the treatment of respiratory conditions, including asthma. The consumption of inhaled corticosteroids, including Budesonide, has grown as a result of government and private programs that inform patients and medical professionals about symptoms, triggers, and management strategies.

 

Restraining Factors

The side effects associated with sneezing, nosebleeds, diarrhea, vomiting, coughing, vomiting, nausea, dry throat, runny nose, headache, etc., and product recall may impede the market growth.

 

Market Segmentation

The global budesonide inhaler market share is classified into product type, usage type, indication, and distribution channel.

• The metered dose inhaler segment dominated the budesonide inhaler market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the product type, the global budesonide inhaler market is categorized into dry powder inhaler and metered dose inhaler. Among these, the metered dose inhaler segment dominated the budesonide inhaler market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is attributed to its patient convenience, precise dose of medication, cost-effective than other types of inhalers, portability, readily availability of medication, no external power source is required, delivery of small droplets of medication of less than 5 μm particles, ease of use, rapid relief from bronchospasm, safe to use, reduce side effects, and rapid onset of action.

 

• The maintenance therapy segment held a significant share in 2023 and is expected to grow at a remarkable CAGR throughout the projected timeframe.

Based on the usage type, the global budesonide inhaler market is categorized into rescue therapy and maintenance therapy. Among these, the maintenance therapy segment held a significant share in 2023 and is expected to grow at a remarkable CAGR throughout the projected timeframe. This segment growth is driven by optimized treatment, stabilizes lung function, provides effective asthma symptom control, patient compliance, long-term consumption of the budesonide for maintenance therapy, provides a low risk of adverse effects, minimizes the systemic side effects, and prevents asthma exacerbations.

 

• The asthma segment accounted for a significant share in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe.

Based on the indication, the global budesonide inhaler market is categorized into chronic obstructive pulmonary disease, allergic rhinitis, and asthma. Among these, the asthma segment accounted for a significant share in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe. The segment expansion is owing to the rising prevalence of asthma attacks globally among adults and pediatrics, budesonide inhalers more effectively manage asthma, genetic predisposition, sedentary lifestyles, and environmental factors that trigger asthma.

 

• The hospital pharmacies segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global budesonide inhaler market is categorized into online pharmacies, hospital pharmacies, and retail pharmacies. Among these, the hospital pharmacies segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The hospital pharmacies segment expansion is accelerated by the availability of critical medicines, accessibility of a wide range of inhalers, provision of dispensing medications, collaborations with hospitals to benefit patient safety and enable the patient comprehensive care, personalized medications, and counseling to patients using budesonide inhalers with understanding aspects.

 

Regional Segment Analysis of the Global Budesonide Inhaler Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global budesonide inhaler market over the predicted timeframe.

Get more details on this report -

Request Free Sample PDF

North America is anticipated to hold the largest share of the global budesonide inhaler market over the predicted timeframe. This is attributed to the rising proportion of asthma patients and COPD patients in the United States. Technological developments in inhaler devices, such as the incorporation of smart technologies for improved patient monitoring and adherence, are driving this growth trend. The need for efficient respiratory therapies is also growing as a result of urban pollution and population aging. In an attempt to accelerate market expansion, several regulatory agencies, such as the FDA in the United States, have implemented steps to expedite the approval procedures for innovative inhaler devices.

 

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is ascribed to the saturation of production and formulation companies and rising clinical trials of medical devices and FDA approvals activities. The region is anticipated to expand as a result of the increasing research and development activities. Key market participants are expected to increase their investments in R&D projects and expand their production capacities and product lines, which will accelerate growth. Developments in technology have assisted the regional market growth.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global budesonide inhaler market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Teva Pharmaceuticals
• Pfizer
• Sandoz
• AstraZeneca
• Novartis
• GlaxoSmithKline
• Cipla
• Myla N.V.
• Reddy’s Laboratories
• Shanghai Sine Pharmaceuticals
• Lupin Limited
• Synmosa Biopharma Corporation
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In November 2024, AstraZeneca Pharma Limited launched the Breztri Aerosphere, an inhalational preparation comprised of Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5mcg. It is indicated for the maintenance treatment to relieve the symptoms and prevent the exacerbation of pulmonary disease (COPD).

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global budesonide inhaler market based on the below-mentioned segments:

 

Global Budesonide Inhaler Market, By Product Type

• Dry Powder Inhaler
• Metered Dose Inhaler

 

Global Budesonide Inhaler Market, By Usage Type

• Rescue Therapy
• Maintenance Therapy

 

Global Budesonide Inhaler Market, By Indication

• Chronic Obstructive Pulmonary Disease
• Allergic Rhinitis
• Asthma

 

Global Budesonide Inhaler Market, By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

 

Global Budesonide Inhaler Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa